A randomized, double-blind, parallel-group, placebo-controlled, active-referenced, fixed-dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder.

Trial Profile

A randomized, double-blind, parallel-group, placebo-controlled, active-referenced, fixed-dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Vortioxetine (Primary) ; Duloxetine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms RELAPSE
  • Sponsors Takeda
  • Most Recent Events

    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 09 Oct 2009 Trial phase changed from II/III to III as reported by ClinicalTrials.gov
    • 19 Jun 2009 Planned number of patients changed from 500 to 611 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top